Angham M. Abed
Angham M. Abed has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Hany Akeel Al-Hussaniy
Department of Pharmacology, College of Pharmacy, Al-nisour University, Baghdad, Iraq
2 shared publications - Maha H. Abdulkadem
Al Safwa University College, Karbala, Iraq
2 shared publications - Ahmed J. Delli
University of Mashreq, Baghdad, Iraq
1 shared publication - Ahmed Saeed Hamad
Albayan University, Baghdad, Iraq
1 shared publication - Alaa Abd Al-Hussain Naem
Alzahraa University for Women, Karbala, Iraq
1 shared publication - Amjad Ibraim Oraibi
Al-Manara College for Medical Sciences, Department of Pharmacy, Amarah, Iraq
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Precision dosing in neonates: AI as a pharmacological tool
The pharmacological therapy of neonates is extremely complicated due to the immature organ systems of the body, high water content, and low number of clinical studies in children of this age. Conventional dosing strategies, usually based on weight or age, are often inaccurate and may result in either underexposure or toxicity. A structured literature search was performed in PubMed/MEDLINE and Scopus, as well as Web of Science, from 2000 to September 2025. The search was based on neonatal pharmacokinetics, model-informed precision dosing (MIPD), Bayesian dosing, and artificial intelligence/machine learning. Following the removal of duplicates and two-stage screening (title/abstract and full-text review), 82 studies were used in the end to conduct this review. This review follows the PRISMA 2020 flow selection style. Pharmacokinetic and pharmacodynamic (popPK/PD) models, with the help of Bayesian strategies, can offer a context for therapy individualization, but they are still limited by the absence of complete information and high intersubjective differences. Artificial intelligence (AI) can also be used to provide an extra level of support by processing vast and multifaceted data, discovering latent trends, and improving dose predictions in real time. This review concluded that applications of AI-driven tools are now emerging in neonatal intensive care, particularly for antibiotics and analgesics, where accurate dosing is critical. Combining AI with known pharmacometric practices could assist clinicians in minimizing adverse drug reactions, enhancing treatment outcomes, and getting closer to actual personalized pharmacotherapy in neonates.
- 21 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessPrecision dosing in neonates: AI as a pharmacological tool
The pharmacological therapy of neonates is extremely complicated due to the immature organ systems of the body, high water content, and low number of clinical studies in children of this age. Conventional dosing strategies, usually based on weight or age, are often inaccurate and may result in either underexposure or toxicity. A structured literature search was performed in PubMed/MEDLINE and Scopus, as well as Web of Science, from 2000 to September 2025. The search was based on neonatal pharmacokinetics, model-informed precision dosing (MIPD), Bayesian dosing, and artificial intelligence/machine learning. Following the removal of duplicates and two-stage screening (title/abstract and full-text review), 82 studies were used in the end to conduct this review. This review follows the PRISMA 2020 flow selection style. Pharmacokinetic and pharmacodynamic (popPK/PD) models, with the help of Bayesian strategies, can offer a context for therapy individualization, but they are still limited by the absence of complete information and high intersubjective differences. Artificial intelligence (AI) can also be used to provide an extra level of support by processing vast and multifaceted data, discovering latent trends, and improving dose predictions in real time. This review concluded that applications of AI-driven tools are now emerging in neonatal intensive care, particularly for antibiotics and analgesics, where accurate dosing is critical. Combining AI with known pharmacometric practices could assist clinicians in minimizing adverse drug reactions, enhancing treatment outcomes, and getting closer to actual personalized pharmacotherapy in neonates.
- Open Access
- 12 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Activation of autophagy via bacterial lipopolysaccharide in breast cancer cells: A molecular approach to enhancing immunotherapeutic outcomes
Background : Autophagy plays a pivotal role in regulating cancer cell survival and death. Leveraging bacterial components, such as lipopolysaccharide (LPS), to modulate autophagy represents a novel strategy in oncologic therapeutics, especially in breast cancer. Objective : To assess the effect of LPS derived from Escherichia coli on the proliferation, viability, and immune signaling pathways in human breast cancer cell lines MCF-7 and MDA-MB-231, with a focus on autophagy induction and Toll-like receptor activation. Methods : LPS was isolated using the phenol–water method from E. coli strains ATCC 8739 and DH5α. Breast cancer cells were treated with varying concentrations of LPS over multiple time intervals (24–72 h). Viability was measured by MTT and CCK-8 assays, while mRNA expression levels of TLR-4, NF-κB, and PIK3C3 were quantified using qRT-PCR following RNA extraction and cDNA synthesis. Results : LPS treatment significantly reduced cell viability in both breast cancer cell lines in a time- and dose-dependent manner. Gene expression analysis revealed robust upregulation of TLR-4 and NF-κB, implicating activation of immune-related signaling. Moreover, increased PIK3C3 expression indicated stimulation of autophagic pathways. At the molecular level, there was an increase in the conversion of LC3-I to LC3-II and degradation of the autophagy substrate P62/SQSTM1, as confirmed by Western blot analysis, indicating enhanced autophagy. The findings confirm LPS’s ability to trigger immune–autophagic responses leading to cytotoxic effects in cancer cells. Conclusion : LPS from E. coli effectively induces autophagy and activates the immune pathway in breast cancer cells, highlighting its dual potential as an immunomodulator and cytotoxic agent. These findings support further exploration of LPS as an adjuvant in breast cancer treatment strategies, particularly in synergy with conventional chemotherapeutic agents.
- 12 February 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, 1-10
Open AccessActivation of autophagy via bacterial lipopolysaccharide in breast cancer cells: A molecular approach to enhancing immunotherapeutic outcomes
Background : Autophagy plays a pivotal role in regulating cancer cell survival and death. Leveraging bacterial components, such as lipopolysaccharide (LPS), to modulate autophagy represents a novel strategy in oncologic therapeutics, especially in breast cancer. Objective : To assess the effect of LPS derived from Escherichia coli on the proliferation, viability, and immune signaling pathways in human breast cancer cell lines MCF-7 and MDA-MB-231, with a focus on autophagy induction and Toll-like receptor activation. Methods : LPS was isolated using the phenol–water method from E. coli strains ATCC 8739 and DH5α. Breast cancer cells were treated with varying concentrations of LPS over multiple time intervals (24–72 h). Viability was measured by MTT and CCK-8 assays, while mRNA expression levels of TLR-4, NF-κB, and PIK3C3 were quantified using qRT-PCR following RNA extraction and cDNA synthesis. Results : LPS treatment significantly reduced cell viability in both breast cancer cell lines in a time- and dose-dependent manner. Gene expression analysis revealed robust upregulation of TLR-4 and NF-κB, implicating activation of immune-related signaling. Moreover, increased PIK3C3 expression indicated stimulation of autophagic pathways. At the molecular level, there was an increase in the conversion of LC3-I to LC3-II and degradation of the autophagy substrate P62/SQSTM1, as confirmed by Western blot analysis, indicating enhanced autophagy. The findings confirm LPS’s ability to trigger immune–autophagic responses leading to cytotoxic effects in cancer cells. Conclusion : LPS from E. coli effectively induces autophagy and activates the immune pathway in breast cancer cells, highlighting its dual potential as an immunomodulator and cytotoxic agent. These findings support further exploration of LPS as an adjuvant in breast cancer treatment strategies, particularly in synergy with conventional chemotherapeutic agents.